Log in
Enquire now
XyloCor Therapeutics

XyloCor Therapeutics

XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.

OverviewStructured DataIssuesContributors

Contents

xylocor.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Regenerative medicine
Regenerative medicine
Biomedical engineering
Biomedical engineering
Biopharmaceutical
Biopharmaceutical
Healthcare
Healthcare
Technology
Technology
Cardiovascular disease
Cardiovascular disease
...
Location
United States
United States
Malvern, Pennsylvania
Malvern, Pennsylvania
Wayne, Pennsylvania
Wayne, Pennsylvania
B2X
B2B
B2B
Legal Name
XyloCor Therapeutics, Inc.
Number of Employees (Ranges)
11 – 500
Full Address
1200 Liberty Ridge Drive, Suite 120, Wayne, PA 19087, US
Investors
Sofinnova Partners
Sofinnova Partners
Lumira Ventures
Lumira Ventures
Longwood Fund
Longwood Fund
0
Founded Date
2013
Total Funding Amount (USD)
58,900,000
Latest Funding Round Date
March 22, 2021
Latest Funding Type
Series A
Series A
Country
United States
United States

Other attributes

Company Operating Status
Active
Short Name
XyloCor
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like XyloCor Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.